Breakthrough Gene Therapy Shows Promise for Recessive Dystrophic Epidermolysis Bullosa Patients
A new gene therapy using prademagene zamikeracel shows promising results in improving wound healing and reducing pain in patients with recessive dystrophic epidermolysis bullosa, a severe genetic skin disorder.
Recent advancements in gene therapy have demonstrated significant benefits for patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disorder characterized by fragile skin and chronic wounds. A groundbreaking study published in The Lancet reports that a single surgical application of prademagene zamikeracel—an autologous cellular sheet modified with the COL7A1 gene—can markedly improve wound healing and reduce pain in affected individuals.
This innovative treatment involves suturing the gene-modified cellular sheet directly onto large, persistent wounds, offering a new hope for those struggling with non-healing wounds. The study was a randomized, open-label phase 3 trial conducted at two centers, involving patients aged 6 years and older who had confirmed diagnoses of RDEB and at least two chronic wounds.
Researchers enrolled eleven patients and matched their wounds in pairs, randomly assigning them to receive either the gene therapy or standard care. Results at 24 weeks revealed that 81% of treated wounds achieved at least 50% healing, compared to only 16% in the control group. Additionally, patients receiving the therapy reported a significant decrease in wound pain—an average reduction of 3.07 points—versus a 0.90-point decrease in controls. Importantly, no serious adverse events related to the treatment were observed.
Dr. Jean Y. Tang from Stanford University summarized, "Our gene therapy approach successfully targeted the most difficult-to-heal wounds, significantly alleviating pain for patients." The study was funded by Abeona Therapeutics, which holds the patent for prademagene zamikeracel.
This promising development marks a stride forward in regenerative medicine for genetic skin diseases, with the potential to transform future treatment options for RDEB and similar conditions.
Source: https://medicalxpress.com/news/2025-06-gene-therapy-effective-patients-recessive.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Gwada-negative: The Rarest Blood Group on Earth
French scientists have discovered the world's rarest blood group, Gwada-negative, found in a woman from Guadeloupe. This groundbreaking finding highlights the complexity of human blood systems and the potential for future personalized transfusion solutions.
Setback in the Fight Against Pediatric HIV
Recent funding reductions threaten groundbreaking research in pediatric HIV cure efforts in Botswana, risking years of progress in the fight against HIV/AIDS in children.
New Blood Test Can Predict Severe Liver Disease Risk
A simple blood test developed by researchers can predict the risk of severe liver disease, enabling earlier diagnosis and intervention in primary care settings. The CORE model uses routine blood parameters to assess long-term liver health risk with high accuracy.
FDA Approves Zoryve Cream for Treating Atopic Dermatitis in Young Children
The FDA has approved Zoryve cream for treating mild-to-moderate atopic dermatitis in children aged 2 to 5, offering a non-steroid topical option backed by clinical trials showing rapid symptom improvement.